Details for New Drug Application (NDA): 019369
✉ Email this page to a colleague
The generic ingredient in TEGISON is etretinate. Additional details are available on the etretinate profile page.
Summary for 019369
Tradename: | TEGISON |
Applicant: | Roche |
Ingredient: | etretinate |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 019369
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 10MG | ||||
Approval Date: | Sep 30, 1986 | TE: | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 25MG | ||||
Approval Date: | Sep 30, 1986 | TE: | RLD: | No |
Expired US Patents for NDA 019369
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Roche | TEGISON | etretinate | CAPSULE;ORAL | 019369-001 | Sep 30, 1986 | 4,200,647 | ⤷ Subscribe |
Roche | TEGISON | etretinate | CAPSULE;ORAL | 019369-002 | Sep 30, 1986 | 4,215,215 | ⤷ Subscribe |
Roche | TEGISON | etretinate | CAPSULE;ORAL | 019369-002 | Sep 30, 1986 | 4,200,647 | ⤷ Subscribe |
Roche | TEGISON | etretinate | CAPSULE;ORAL | 019369-001 | Sep 30, 1986 | 4,215,215 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription